natgillin/translations-raw huggingface dataset:
If necessary, pH of the solution is adjusted to between 4 and 7: Procedure 
Ako je potrebno, pH otopine se podesi da bude između 4 i 7.
In one aspect of the present invention, the DPP-IV inhibitor is an inhibitor of human DPP-IV. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da DPP-IV inhibitor je inhibitor humanog DPP-IV.
A method for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of the compound, a pharmaceutically acceptable salt thereof, or a prodrug thereof as set forth in 1. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa melitusa, dijabetične retinopatije, dijabetične neuropatije, dijabetične nefropatije, usporenog zarastanja rana, otpornosti na inzulin, hiperglikemije, hiperinzulinemije, povišenih razina masnih kiselina u krvi, povišenih razina glicerola u krvi, hiperlipidemije, pretilosti, hipertrigliceridemije, Sindroma X, komplikacija dijabetesa, ateroskleroze ili hipertenzije.
An attenuated Newcastle disease virus (NDV) 73T strain wherein the wild type F protein cleavage site (FPCS) having the amino acid sequence 111G-R-R-Q-K-R/F117 is modified, and wherein the modified F protein cleavage sequence (FPCS) comprises a sequence selected from the group consisting of: 
PATENTNI ZAHTJEVI Ublaženi virus Newcastleske bolesti soj (NDV) 73T pri čemu je modificirano mjesto cijepanja divljeg tipa F proteina (FPCS) koje ima sekvencu aminokiseline 111G-R-R-Q-K-R/F117, te pri čemu modificirana sekvenca cijepanja F proteina (FPCS) sadrži sekvencu odabranu iz skupine koja se sastoji od:
According to a first aspect of the invention, a jar for use in a downhole toolstring comprises: 
Prema prvom aspektu izuma udarac koji se koristi u alatu za bušenje, sadrži:
The compound of claim 19 wherein the effective amount of the compound of claim 1 is from about 0.001mg/kg/day to about 300mg/kg/day. 
Spoj u skladu sa zahtjevom 19, naznačen time, da je učinkovita količina spoja u skladu sa zahtjevom 1 od oko 0.001 mg/kg/dan do oko 300 mg/kg/dan.
In some embodiments the radionuclide 3H and/or 14C isotopes are useful in these studies. 
U nekim oblicima, radionukleotid *H i/ili '*C izotopi su korisni u navedenim proučavanjima.
A compound of claim 1 having the following formula A compound of claim 1 having the following formula The use of a quinazolinone compound as defined in any of claims 1 to 4 for the manufacture of a medicament for the treatment or prevention of a disease or condition, in which vanilloid receptor activation plays a role or is implicated. 
Rs je vodik ili hidroksi; i mje lili2, u slobodnom obliku ili u obliku soli, 1, gdje je to moguće, u obliku kiselinske adicijske soli, koristi za proizvodnju lijeka za liječenje ili prevenciju bolesti ili stanja u kojem ima ulogu aktivacija vaniloid receptora ili je ona u to uključena.
The process according to any one of claims 1 to 11, characterised in that said mineral material is selected from among metal oxides such as titanium dioxide and/or aluminium trioxide, metal hydroxides such as aluminium trihydroxide, sulphites, silicates such as talc and/or kaolin clay and/or mica, carbonates such as calcium carbonate and/or dolomite, gypsum, satin white and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time što se mineralni materijal izabire između metalnih oksida kao što je titanijev dioksid i/ili aluminijev trioksid, metalnih hidroksida kao što je aluminijev trihidroksid, sulfita, silikata kao što je talk i/ili kaolin glina i/ili tnjac (mica), karbonata kao što je kalcijev karbonat i/ili dolomit, gips, saten bijelo te njihovih smjesa.
The expression vector of claim 6, wherein the composition is administered to an animal at a dosage range from about 105 pfu to about 109 pfu. A method of vaccinating an animal comprising at least one administration of the composition or expression vector of claim 1 or 6 . 
Sastav ili vektor ekspresije prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se upotrebljava kao životinjsko cjepivo, pri čemu se sastav ili vektor ekspresije formulira za najmanje jedno davanje.
A leakage plugging device according to claim 1, wherein said at least one sealant composition comprises two sealant compositions. A leakage plugging device according to claim 14, wherein said deformable material comprises polyurethane of a density of 15-30 kg/m3, and said at least one sealant composition further comprises a fatty acid liquid composition. 
Uređaj (100) za popunjavanje pukotina sukladno patentnom zahtjevu 10, pri čemu navedeni polimerni materijal koji se može deformirati je gustoće od 15-30 kg/m3, i navedena najmanje jedna tvar za brtvljenje nadalje obuhvaća tekuću tvar masne kiseline, pri čemu poželjno navedena tekuća tvar masne kiseline sadrži biljno ulje.
The vaccine composition according Claim 1 wherein the conjugation ratio between rP64K carrier protein and the hrEGF is 12.04:24.05 nmolar. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da konjugacijski omjer između rP64K nosača proteina i hrEGF je 12,04:24,05 nmola.
The compound of claim 1, characterized by the structure of formula IX: 
LS 5. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom IX:
n: an integer selected from 1, 2, 3, and 4. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound represented by the general formula (I) is a compound represented by general formula (I'): 
Spoj ili njegova farmakološki prihvatljiva sol, ili hidrat spoja ili njegova farmakološki prihvatljiva sol, u skladu sa patentnim zahtjevom 1, gdje spoj koji je predstavljen općom formulom (I) je spoj predstavljen općom formulom (I'): [image]
The rim block cage according to one of the preceding claims, characterized in that spacer elements (14a, 14b) are formed in at least one, preferably in all containers (3a, 3b, 3c, 3d), which space the preparation (4a, 4b, 4c, 4d) apart from the outlet opening (6a, 6b, 6c, 6d). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su elementi za održavanje razmaka (14a, 14b) oblikovani u barem jednom, poželjno u svim spremnicima (3a, 3b, 3c, 3d), koji razmiču pripravke (4a, 4b, 4c, 4d) dalje od izlaznih otvora (6a, 6b, 6c, 6d).
This patent emphasizes the need of micronization and further wetting ass the oral administration of nebivolol hydrochloride is impeded by the poor dissolution when in a normal crystalline form in order to achieve a good dissolution the active ingredient has to be sufficiently wetted. 
Ovaj patent naglašava potrebu za mikronizacijom 1 daljnjim vlaženjem budući je oralna primjena nebivolol hidroklorida ometana slabim otapanjem kada je u normalnom kristalnom obliku da bi se postiglo dobro otapanje aktivna tvar se mora dovoljno vlažiti.
Examples of cancers include, but are not limited to, breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine body cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma, neuroblastoma, ovarian cancer, head and neck cancer, testicular tumor, colorectal cancer, blood cancer, retinoblastoma and pancreatic cancer. 
33. Lijek, spoj ili njegova sol, ili kristal istog, ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 32, gdje je rak odabran od raka dojke, raka debelog crijeva, raka prostate, raka pluća, raka želuca, raka jajnika, raka endometrija, raka bubrega, hepatocelularnog karcinoma, raka tiroide, raka maternice, raka ezofagusa, karcinoma skvamoznih stanica, leukemije, osteosarkoma, melanoma, glioblastoma, neuroblastoma i raka gušterače.
The security element according to claim 1, wherein said flakes are selected from the group consisting of thin-film interference pigments and liquid crystal polymer pigments. 
Sigurnosni element u skladu s patentnim zahtjevom 5, naznačen time, da su navedene ljuske pigmenta (3) odabrane iz skupine koja se sastoji od tankoslojnih interferentnih pigmenata i pigmenata od polimernog tekućeg kristala.
applying pressure to the peripheral flange to seal the lidding film to the container. A process according to claim 21, wherein pressure is applied to the peripheral flange at a pressure of from 30 psi to 180 psi for a period of time of from 0.5 seconds to 5 seconds, preferably 110 psi for 1 second. 
Postupak prema Zahtjevu 18, gdje se na prirubnicu izvedenu duž oboda djeluje tlakom od 206,84 kPa do 1.241,06 kPa (30 psi do 180 psi) tijekom perioda vremena od 0,5 s do 5 s, a poželjno 758,42 kPa (110 psi) tijekom perioda od 1 sekunde.
The method as claimed in claim 1, wherein said step of forming the tablet (C) by compression of said moistened dose is substantially uniformly carried out within a closed compression chamber (11) with a shape complementary to a shape of said tablet (C). 
Postupak sukladno zahtjevu 1, pri čemu se kompresija doze praškastog proizvoda u osnovi izvodi u zatvorenoj kompresijskoj komori (11) oblika komplementarnog navedenoj tableti (C).
the Fc domain comprises a hinge domain, a CH2 domain and a CH3 domain; and/or a leader sequence, such as the human VK3LP peptide, is coupled to the N-terminus of the RNase. 
(c) Fc domena sadrži zglobnu domenu, CH2 domenu i CH3 domenu; i/ili (d) vodeća sekvenca, kao što je ljudski VK3LP peptid, spojena je na N-terminalni kraj RNaze ili N-terminalni kraj DNaze.
In accordance with this embodiment, ozone gas from the ozone operating system 115 is distributed to a medical instrument through an ozone distribution line 118, and the distribution line 118 is fluidly connected to the ozone operating system for receiving and distributing ozone gas. 
Uređaj CPAP (105) u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima mjerač vremena ugrađen u ozonski uređaj (100) radu upravljanja radom sustava za rad s ozonom (115) i, specifičnije, otpuštanja ozona u uređaj CPAP (105).
condensing an a, B-unsaturated ketone derivative represented by the formula (VII): wherein R3, X and m are as defined above, and the compound of the above formula (V); 
[image] pri čemu su R3, X i m kao što je definirano gore, a spoj sa gore navedenom formulom (V); [image] oksidiranje spoja prikazan formulom (I-2):
The method as in any one of the preceding embodiments, wherein the liquid binder is a blank ink (11) comprising a liquid substance that is applied by a digital drop application head (30'). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što je tekuće vezivo bezbojna tinta (11) koja sadrži tekuću supstancu koja se primjenjuje pomoću digitalne aplikacijske glave (30).
subsequently to said heating and pressurisation steps contacting said organic material in said fluid with a heterogeneous catalyst comprising a compound of at least one element of group IVB of the periodic table and/or alpha-alumina 
<nakon navedenih koraka zagrijavanja i tlačenja, dovođenje u kontakt navedenog organskog materijala u navedenoj tekućini s heterogenim katalizatorom koji obuhvaća tvar barem jednog elementa grupe IVB periodičnog sustava i/ili alfa-alumina
filling the sterile reservoir of the container with a volume of a drug product under sterile conditions, wherein the drug product comprises a granulocyte colony-stimulating factor (G-CSF); 
količinu lijeka (520, 680, 750) ubačenu u sterilni rezervoar (510, 670, 740), pri čemu lijek (520, 680, 750) sadrži faktor poticanja rasta granulocitnih kolonija (engl. granulocyte colony-stimulating factor; G-CSF);
Aspect 11. The system of aspect 1 wherein the elongate wick comprises a polymeric material, a ceramic material, or a combination of polymeric and ceramic materials. 
Sustav (10) prema zahtjevu 1, pri čemu izduženi fitilj (30) sadrži polimerni materijal, keramički materijal ili kombinaciju polimernih i keramičkih materijala.
sucrose in an amount of from about 5% to about 10% w/v; and 
(iv) saharozu u količini od 5 % do 10 % w/vy;1
is a hydrogen atom, a C1-6 alkyl group or a C3-8 cycloalkyl group, wherein the C1-6 alkyl group and the C3-8 cycloalkyl group may be substituted with 1 to 4 substituents which are the same or different and are selected from the following group of substituents, Rc, and the group of substituents, Rc, consists of a halogen atom, a hydroxy group, a C1-6 alkyl group, a C1-6 hydroxyalkyl group, a C1-6 haloalkyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group a C3-8 cycloalkoxy group, a C2-6 alkanoyl group, a C1-6 alkylidene group and a hydroxyaminocarbonyl group; wherein the C1-6 alkoxy group may be substituted with 1 to 3 hydroxy groups or halogen atoms; the C1-6 alkylidene group may be substituted with a C1-6 alkoxy group. 
je vodikov atom, skupina C1-6 alkil ili skupina C3-8 cikloalkil, pri čemu skupina C1-6 alkil i skupina C3-8 cikloalkil mogu biti supstituirane s 1 do 4 supstituenata koji su isti ili različiti i odabrani su iz slijedeće skupine supstituenata, Rc, te skupina supstituenata, Rc, sadrži halogeni atom, hidroksi skupinu, skupinu C1-6 alkil, skupinu C1-6 hidroksialkil, skupinu C1-6 haloalkil, skupinu C3-8 cikloalkil, skupinu C1-6 alkoksi, skupinu C3-8 cikloalkoksi, skupinu C2-6 alkanoil, skupinu C1-6 alkiliden i skupinu hidroksiaminokarbonil; pri čemu skupina C1-6 alkoksi može biti supstituirana s 1 do 3 hidroksi skupine ili halogenih atoma; skupina C1-6 alkiliden može biti supstituirana sa skupinom C1-6 alkoksi.
Compounds XVIII have R6—R9, R′, and R″ as defined previously. 
Spojevi XVIII imaju R"-R*, R' i R" prema definiciji kao gore.
The crude is triturated with ethyl acetate (200 ml) and the resulting solid is filtered and dissolved in water/dioxane (250 ml of a 2:1 mixture). 
Sirov proizvod se triturira s etil acetatom (200 ml) i dobivenu krutu tvar se odfiltrira i otopi u voda/dioksanu (250 ml 2:1 mješavine).
Ways of carrying out of the Invention 
Datum objave europske prijave patenta:
Method for treating water at low cost, which will be used in industrial processes, that purifies the water and eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the method comprising: 
Uređaj obuhvaća sustav za izvođenje industrijskog postupka i sustav s niskim troškovima koji uklanja otopljene čvrste čestice filtriranjem male frakcije ukupnog volumena vode, uređaj obuhvaća:
Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia. 
Stoga, na primjer, acilna skupina poput alkanoilne ili aroilne skupine može biti uklonjena, na primjer, hidrolizom pomoću prikladne baze, poput hidroksida alkalijskih metala, primjerice litij ili natrij hidroksida ili amonijaka.
The reaction was worked up by adding 10mL EtOAc to the bottle to dilute the reaction solution then saturated sodium bicarbonate was slowly added to the bottle to neutralize the HF. 
Reakcijska smjesa je bila dorađena dodavanjem 10 mL EtOAc u tikvicu da bi se razrijedila reakcijska otopina 1 tada je zasićeni natrijev bikarbonat bio lagano dodavan u tikvicu da bi se neutralizirao HF.
The immunogenic composition of any preceding claim comprising a S. pneumoniae capsular saccharide derived from a strain selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. The immunogenic composition of any preceding claim comprising a S. typhi Vi capsular saccharide. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije S. pneumoniae kojeg se dobiva iz soja kojeg se bira iz skupine koju čine serotipovi 1, 2, 3, 4, 5, 6A, 6B, TF, 8, 9N, 9V, 10A, IA, 12F, 14, 15B, I7F, 18C, 19A, 19F, 20, 22F, 23F 133F.
MMVF substrates made according to the invention exhibit improved air flow resistivity. Preferably, when the density of the MMVF substrate is in the range 60 to 150 kg/m3 the air flow resistivity is in the range 100 to 200 kPa*s/m2, preferably in the range 120 to 180 kPa*s/m2. 
MMF supstrat sukladno zahtjevu 16 ili 17, naznačen time, što je gustoća MMVF supstrata u rasponu 15 do 250 kg / m3, poželjno u rasponu od 20 kg/m3 do 180 kg/m3, posebno poželjno u rasponu od 60 kg/m3 do 150 kg/m3.
The extended release dosage form of claim 9, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 13, naznačen time da je opioidni analgetik odabran iz skupine kodeina, morfina, oksikodona, hidrokodona, hidromorfona, ili oksimorfona ili njihovih farmaceutski prihvatljivih soli, hidrata ili solvata, smjese bilo kojeg od prethodno navedenih.
N×(70 to 130) g/L PEG having an average molecular weight of 2500 to 4500; 
(a) N x(70 do 130) g/I polietilen-glikola (PEG) prosječne molekulske težine od 2500 do 4500;
According to a preferred embodiment of the present invention 24-nor-ursodeoxycholic acid and salts and esters thereof can be formulated for oral or intravenous administration, wherein these formulations further comprise pharmaceutically acceptable carriers, adjuvants, excipients and/or vehicles. 
- Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevu 1, naznačene time, da su norursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
determining whether there is a decrease in the levels of the soluble molecule between the first and second biological samples, wherein the decrease correlates with a decrease in alpha-4 integrin activity in the individual, and thereby determining whether there is a difference in alpha-4 integrin activity in the individual after administration of the alpha-4 integrin inhibitor compared with before administration of the alpha-4 integrin inhibitor; and 
određivanje postoji li smanjenje u razinama topive molekule između prvog i drugog biološkog uzorka, pri čemu smanjenje korelira sa smanjenjem alfa-4 integrinske aktivnosti kod pojedinca, i time određuje postoji li razlika u alfa-4 integrinskoj aktivnosti kod pojedinca nakon primjene alfa-4 integrinskog inhibitora u usporedbi sa prije primjene alfa-4 integrinskog inhibitora; i
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art. 
Postupci sinteze za ugradnju radio-izotopa u organske spojeve su primjenjivi na spojeve prema izumu i dobro su poznati u struci.
Advantageous embodiments of such a post are defined by the claims 1 to 14 and according to the above description. Dental post consisting of fibre-reinforced material with substantially uniformly directed fibers (8) and mountable in a tooth root canal for fixing a dental prosthetic structure on a tooth stump, wherein said post comprises a tapered portion extending over at least one third of its total length towards its proximal end (4), characterized in that at least one longitudinal groove (5, 6, 7) is provided on the circumferential surface of said tapered portion extending over part of its circumference or at most twice around its circumference. 
Zubni potporanj koji se sastoji od vlaknima ojačanog materijala čija, su vlakna uglavnom jednolično usmjerena (8) i može se ugraditi u kanal korijena zuba radi učvršćivanja strukture zubne proteze na batrljku zuba, gdje navedeni potporanj sadrži suženi dio koji se pruža najmanje jednom trećinom njegove ukupne duljine prema njegovom prednjem kraju (4), naznačen time što se najmanje jedan utor (5, 6, 7), načinjen na obodnoj površini navedenog suženog dijela, pruža uzduž navedenog potpornja, s nagibom u odnosu na uzdužnu os navedenog potpornja po dijelu opsega ili najviše dvaput okolo opsega navedenog suženog dijela.
A method for preparing a compound of Formula (I) or a tautomer, stereoisomer, ester, prodrug, or pharmaceutically acceptable salt thereof wherein, each R1 is independently selected from hydroxy, halo, C1-6 alkyl, C1-6 alkoxy, (C1-6 alkyl)sulfanyl, (C1-6 alkyl)sulfonyl, cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl; 
Spoj prema zahtjevu 1, naznačen time, da svaki R1 je neovisno odabran iz skupine koju čine hidroksi, kloro, fluoro, bromo, metil, etil, propil, butil, metoksi, etoksi, propoksi, butoksi, trifluorometil, trifluoroetil, trifluorometoksi, trifluoroetoksi, piperidinil, C1-6 alkilpiperidinil, piperazinil, C1-6 alkilpiperazinil, tetrahidrofuranil, piridinil i pirimidinil. Spoj prema zahtjevu 1, naznačen time, da a je 1 ili 2, a barem jedan R1 je halo(C1-6 alkil).
s is 1 to 6; t is 0 to 6; and u is 0 to 3; and, wherein a bond bisected by a wavy line signifies a point of attachment. 
s je 1 do 6; t je 0 do 6; i u je 0 do 3; te, pri čemu veza presječena valovitom linijom označava točku vezanja.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2. The method according to claim 9, wherein said antigen-presenting cell comprises an expression vector expressing said peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2,pri čemu opcionalno stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
Cortexolone-17a-propionate in crystalline form III according to claim 15, characterised by a DRX spectrum as represented in Figure 13 and a DSC spectrum as represented in Figure 14, and by an IR spectrum as represented in Figure 15. 
Korteksolon-17a-propionat u kristalnom obliku III u skladu s patentnim zahtjevom 15, naznačen time što ima DR.X spektar, kao što je prikazan na Slici 13 1 DSC spektar, kao što je prikazan na Slici 14, te što ima IR spektar, kao što je prikazan na Slici 15.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se norursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.